Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 6:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Acute Hospitalization Clear all
Completed Phase 3 Interventional Results available

A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE)

NCT01323153
View directory record Official record
Conditions
Coronary Heart Disease
Interventions
dalcetrapib, placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
45 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
6
States / cities
Pensacola, Florida • Saginaw, Michigan • Saint Cloud, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2019 · Synced Jul 23, 2026, 6:24 PM EDT
Not yet recruiting Not applicable Interventional

A Study Of Acute Decompensated Heart Failure

NCT07572955
View directory record Official record
Conditions
Acute Decompensated Heart Failure
Interventions
Lung Ultrasound
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Jul 23, 2026, 6:24 PM EDT
Recruiting Phase 4 Interventional

A Pragmatic Clinical Trial Comparing the Risk of Acute Kidney Injury During Treatment With Vancomycin and Piperacillin-Tazobactam vs. Vancomycin and Cefepime in Hospitalized Patients

NCT06954129
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Vancomycin, Piperacillin-tazobactam, Cefepime
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Jul 23, 2026, 6:24 PM EDT
Completed Not applicable Interventional

Balance, Aerobic Capacity, Mobility and Strength in Patients Hospitalized for Heart Failure (BAMS-HF) Program

NCT04281849
View directory record Official record
Conditions
Heart Failure, Heart Failure With Preserved Ejection Fraction, Heart Failure, Systolic, Heart Failure, Diastolic, Heart Failure，Congestive, Heart Failure; With Decompensation, Heart Failure Acute, Heart Failure With Reduced Ejection Fraction
Interventions
BAMS-HF Program
Behavioral
Lead sponsor
VA Eastern Colorado Health Care System
Federal
Eligibility
55 Years to 100 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 22, 2023 · Synced Jul 23, 2026, 6:24 PM EDT
Completed Phase 2 Interventional Results available

COVID-19 Study Assessing the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Adult Outpatients With SARS-CoV-2 Infection

NCT04666441
View directory record Official record
Conditions
COVID-19
Interventions
REGN10933+REGN10987 combination therapy, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
57
States / cities
Mesa, Arizona • Tucson, Arizona • Canoga Park, California + 48 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2022 · Synced Jul 23, 2026, 6:24 PM EDT
Completed Not applicable Interventional Results available

Short Stay Unit vs Hospitalization in Acute Heart Failure

NCT03302910
View directory record Official record
Conditions
Acute Heart Failure
Interventions
Short Stay Unit, Standard of Care
Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 99 Years
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
11
States / cities
Birmingham, Alabama • Indianapolis, Indiana • Detroit, Michigan + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Jul 23, 2026, 6:24 PM EDT
Completed Phase 4 Interventional

Bupropion for Hospitalized Smokers With Acute Cardiovascular Disease

NCT00181818
View directory record Official record
Conditions
Smoking, Myocardial Infarction, Unstable Angina, Cardiovascular Disease
Interventions
bupropion SR (sustained-release)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 15, 2005 · Synced Jul 23, 2026, 6:24 PM EDT
Active, not recruiting Phase 2 Interventional

Study to Investigate the Efficacy of Abrocitinib in Adult Participants With Severe Fatigue From Post COVID Condition/Long COVID

NCT06597396
View directory record Official record
Conditions
Post-COVID Condition, Fatigue Symptom
Interventions
Abrocitinib, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Jul 23, 2026, 6:24 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Maternal Mental Health in the Hospital Setting

NCT03777046
View directory record Official record
Conditions
Post Partum Depression
Interventions
Standard of Care (SOC), SOC with Psychology Therapy (CBT)
Behavioral
Lead sponsor
Michelle Lopez
Other
Eligibility
18 Years and older · Female only
Enrollment
545 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 13, 2023 · Synced Jul 23, 2026, 6:24 PM EDT
Completed Phase 4 Interventional Results available

Comparison of Sacubitril/Valsartan Versus Enalapril on Effect on NT-proBNP in Patients Stabilized From an Acute Heart Failure Episode.

NCT02554890
View directory record Official record
Conditions
Acute Heart Failure
Interventions
sacubitril/valsartan (LCZ696), Enalapril, sacubitril/valsartan (LCZ696) matching placebo, enalapril matching placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
887 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
123
States / cities
Birmingham, Alabama • Fort Smith, Arkansas • Little Rock, Arkansas + 105 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced Jul 23, 2026, 6:24 PM EDT
Completed Not applicable Interventional

Human Algorithm Interactions for Acute Respiratory Failure Diagnosis

NCT06098950
View directory record Official record
Conditions
Acute Respiratory Failure
Interventions
Artificial Intelligence model predictions without explanation, Artificial intelligence model predictions with explanation, AI model biased against heart failure, AI model biased against pneumonia, AI model biased against COPD
Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
457 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 24, 2023 · Synced Jul 23, 2026, 6:24 PM EDT
Recruiting Phase 3 Interventional

A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients

NCT06008197
View directory record Official record
Conditions
Heart Failure, Acute Heart Failure
Interventions
Finerenone, Placebo
Drug
Lead sponsor
Colorado Prevention Center
Other
Eligibility
18 Years and older
Enrollment
5,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
80
States / cities
Birmingham, Alabama • Fairhope, Alabama • Huntsville, Alabama + 70 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Jul 23, 2026, 6:24 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Airflow Obstruction and Biomarkers of Airway Inflammation During and Following Acute Exacerbations of Childhood Asthma

NCT01227070
View directory record Official record
Conditions
Asthma
Interventions
Not listed
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
6 Years to 18 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 21, 2010 · Synced Jul 23, 2026, 6:24 PM EDT
Completed No phase listed Observational

Determining When Patients Hospitalized With Acute Heart Failure Can Be Safely Sent Home (The DECIDE Study)

NCT00911703
View directory record Official record
Conditions
Acute Heart Failure
Interventions
Not listed
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
835 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
2
States / cities
Cincinnati, Ohio • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 28, 2016 · Synced Jul 23, 2026, 6:24 PM EDT
Not listed Phase 3 Interventional

Evaluation of the Efficacy and Safety of Intravenous Imipenem/Cilastatin/XNW4107 in Comparison With Meropenem in Hospitalized Adults With cUTI Including AP (EudraCT no. 2022-000061-40)

NCT05204368
View directory record Official record
Conditions
Complicated Urinary Tract Infection Including Acute Pyelonephritis
Interventions
Combination of Imipenem/Cilastatin and XNW4107, Meropenem
Drug
Lead sponsor
Evopoint Biosciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
780 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Jul 23, 2026, 6:24 PM EDT
Recruiting Phase 2 Interventional

JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort A: Vilobelimab

NCT06701682
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome), Acute Respiratory Distress Syndrome
Interventions
Cohort A: vilobelimab, Cohort A: placebo
Drug
Lead sponsor
PPD Development, LP
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
40
States / cities
Birmingham, Alabama • Fresno, California • Long Beach, California + 33 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Jul 23, 2026, 6:24 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study to Determine the Safety and Effectiveness of Azeliragon in the Treatment of Patients Hospitalized for Coronavirus Disease 2019 (COVID-19) or Pneumonia

NCT05815485
View directory record Official record
Conditions
COVID-19
Interventions
Azeliragon, Placebo
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Chicago, Illinois • Ann Arbor, Michigan • Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 2, 2025 · Synced Jul 23, 2026, 6:24 PM EDT
Withdrawn Phase 2 Interventional

A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People With Weakened Immune Systems or at Increased Risk for Poor Outcomes Who Are Hospitalized Due to Severe COVID-19

NCT05545319
View directory record Official record
Conditions
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Coronavirus Disease 2019 (COVID-19), Immunocompromised, Hospitalization, Child, Hospitalized
Interventions
Nirmatrelvir, Ritonavir, Placebo for nirmatrelvir
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Cooperstown, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 28, 2023 · Synced Jul 23, 2026, 6:24 PM EDT
Completed Phase 3 Interventional Results available

VIR-7831 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

NCT05780281
View directory record Official record
Conditions
COVID-19
Interventions
VIR-7831, Placebo, Remdesivir
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
367 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
74
States / cities
Tucson, Arizona • Fresno, California • Loma Linda, California + 50 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2023 · Synced Jul 23, 2026, 6:24 PM EDT
Terminated No phase listed Observational

Home-Based Fluid Status Monitoring in Heart Failure Patients

NCT04013373
View directory record Official record
Conditions
Heart Failure
Interventions
SOZO Bioimpedance Spectroscopy Device
Device
Lead sponsor
ImpediMed Limited
Industry
Eligibility
21 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
15
States / cities
Canoga Park, California • Encinitas, California • Garden Grove, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2021 · Synced Jul 23, 2026, 6:24 PM EDT
Not yet recruiting Not applicable Interventional

Why Wait? Initiating Contingency Management in Traumatically Injured Patients During Hospitalization

NCT06931197
View directory record Official record
Conditions
Contingency Management, Methamphetamine Use Disorder
Interventions
Contingency management
Behavioral
Lead sponsor
Queen's Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Jul 23, 2026, 6:24 PM EDT
Recruiting Phase 2 Interventional

Study of Efficacy and Safety of Tonlamarsen in Participants With a Recent Hospitalization and a Concurrent Episode of Acute Severe Hypertension

NCT07511361
View directory record Official record
Conditions
Hypertension, Acute Severe Hypertension, Hypertensive Emergency, Hypertensive Urgency
Interventions
Tonlamarsen, Placebo
Drug
Lead sponsor
Kardigan, Inc.
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
8
States / cities
Arvada, Colorado • Homestead, Florida • Port Orange, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Jul 23, 2026, 6:24 PM EDT
Completed Phase 2 Interventional

A Study to Explore the Efficacy of TRV027 in Patients Hospitalized for Acute Decompensated Heart Failure

NCT01966601
View directory record Official record
Conditions
Acute Decompensated Heart Failure
Interventions
TRV027 Dose #1, TRV027 Dose #2, TRV027 Dose #3, Placebo
Drug
Lead sponsor
Trevena Inc.
Industry
Eligibility
21 Years to 85 Years
Enrollment
620 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
4
States / cities
Detroit, Michigan • Cincinnati, Ohio • Tullahoma, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2018 · Synced Jul 23, 2026, 6:24 PM EDT
Not yet recruiting Phase 3 Interventional

Early Discharge With Subcutaneous Furosemide Versus Standard Care in Acute Heart Failure

NCT07018297
View directory record Official record
Conditions
Heart Failure, Acute Decompensated Heart Failure
Interventions
Early Discharge with Lasix® ONYU (furosemide injection, for subcutaneous use) using SQIN-Infusor
Combination Product
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 100 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Jul 23, 2026, 6:24 PM EDT